Stocktoria
Tanke Biosciences Corp TNBI
OTC · stock · Grain Mill Products · website · IPO 2011-02-10
Tanke Biosciences Corp financials (annual, from 10-K)
Bars are annual figures from 2010 to 2012; red bars are negative (a loss or cash outflow).
| Metric | FY2012 | FY2011 | FY2010 |
|---|---|---|---|
| Revenue | $28.6M | $23.8M | $20.1M |
| Gross profit | $9.9M | $8.8M | $7.4M |
| R&D expense | $290,691 | $246,038 | — |
| Operating income | $4.5M | $1.7M | $4.4M |
| Interest expense | $1.4M | $1.4M | $100,265 |
| Income tax | $831,597 | $681,321 | $582,493 |
| Net income | -$210,247 | -$3.1M | $2.7M |
| EPS (diluted) | — | $-0.24 | $0.34 |
| Operating cash flow | -$1.2M | $3.5M | $4.4M |
| Free cash flow | -$2.0M | $2.8M | $4.3M |
| Cash & equivalents | $6.2M | $7.7M | $2.2M |
| Inventory | $1.4M | $1.2M | $1.4M |
| Total assets | $28.8M | $24.9M | $13.3M |
| Total liabilities | $12.9M | $9.0M | $2.9M |
| Shareholders' equity | $15.9M | $15.9M | $10.3M |
Growth · year-over-year · Revenue CAGR 19.2%
| Metric | FY2012 | FY2011 | FY2010 |
|---|---|---|---|
| Revenue growth | +19.8% | +18.6% | — |
| Net income growth | — | -214.5% | — |
| EPS growth | — | -170.6% | — |
| Free cash flow growth | -171.8% | -34.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001452011 · US · as of 2012-12-31. facts plus Stocktoria's own computed scores — not investment advice.